knowledge -WSS

knowledge

author：leisure time 2025-09-07 11:15:55 - browse：322

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Curing rare childhood diseases will falter unless Congress steps up

entertainment

knowledge

WSS

Cigna wins case to block Amy Bricker's move to CVS

'Essentially witchcraft:' A former naturopath takes on the field

New Alzheimer's drugs heat up race for early detection blood tests

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Cheap, fast test for Zika and dengue could cost just $1

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Hollywood unions extend contract negotiations for actors

Rise in cancer among younger people worries and puzzles doctors

Medicare details structure of new drug price negotiation program

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Duchenne breakthrough therapy leaves behind pioneering families

Deposition: Sackler embraced plan to conceal OxyContin’s strength

New air purifier tech could be key to improving indoor air quality

Democrats decry new health bill for going easy on private equity

New air purifier tech could be key to improving indoor air quality

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Wikipedia

Democrats decry new health bill for going easy on private equity

Biden warns of ‘dark winter’ during final presidental debate

'Investigate these claims': UFO transparency at center of House hearing

Health care court cases: Humana, Sutter, Novant

New Alzheimer's drugs heat up race for early detection blood tests

Deposition: Sackler embraced plan to conceal OxyContin’s strength

entertainment

knowledge

explore

hotspot